临床与病理杂志2017，Vol.37Issue(4)：868-871,4.DOI:10.3978/j.issn.2095-6959.2017.04.037
药物基因组学影响肾移植术后他克莫司疗效的研究进展
Research progress of pharmacogenomics on the curative effect of tacrolimus after renal transplantation
李欢1
作者信息
- 1. 南华大学药物药理研究所,湖南衡阳421001
- 折叠
摘要
Abstract
Tacrolimus (Tacrolimus,FK506) is a calcineurin inhibitor isolated from Streptomyces,and it is a first-line immunosuppressive agent for the prevention of organ transplant rejection.Tacrolimus is an immunosuppressive agent with good therapeutic effect.However,the narrow therapeutic window and pharmacokinetics of individual differences easily lead to insufficient immunosuppression or excessive immunosuppression and adverse reactions induced by renal toxicity and diabetes,which remains a critical problem in clinical practice.关键词
他克莫司/药物基因组学/CYP3A/MDR1/SUMO4Key words
tacrolimus/pharmacogenomics/CYP3A/MDR1/SUMO4引用本文复制引用
李欢..药物基因组学影响肾移植术后他克莫司疗效的研究进展[J].临床与病理杂志,2017,37(4):868-871,4.
